ÂÜÀòÂÒÂ×

John F. Reilly has a diverse work experience in the biotech and pharmaceutical industries. John F. is currently the Chief Scientific Officer at Nereid Therapeutics. Prior to this, they worked as an Entrepreneur-in-Residence at ATP Life Science Ventures, where they played a key role in driving biotech company nucleation and advancing companies through funding rounds.

Before that, Reilly held positions at Goldfinch Bio, where they served as Senior Vice President, Biology, and Vice President, Biology. In these roles, they validated novel targets identified from patient genetic data, developed assays to enable drug discovery efforts, and led in vivo pharmacology and biomarker development efforts.

Reilly also worked as the Executive Director, Biology at Catabasis Pharmaceuticals, Inc., where they developed and executed the research strategy for the company's portfolio of preclinical compounds, and as the Global Head, Applied Human Genetics & Genomics at Novartis Institutes for BioMedical Research. In this role, they drove advancements in genomic technologies and provided genomics expertise to early and late stage clinical programs.

Prior to that, Reilly was Director, Molecular Biomarkers, and Senior Principal Scientist, Target & Pathway Biology at Merck Research Laboratories. John F. led a group performing assay development and analyses in support of multiple drug development programs, and served as Biomarker Lead on Discovery, Early- and Late-Stage Development programs.

Reilly began their career as a Senior Scientist at Neurome, Inc., where they applied quantitative neuroanatomical expertise to the analysis of animal models of neurodegenerative disorders and developed a high-resolution three-dimensional digital atlas of the mouse brain. John F. also worked as a Postdoctoral Fellow at The Scripps Research Institute, examining growth factor signal transduction and protein-protein interactions.

Overall, Reilly's extensive work experience showcases their expertise in driving scientific innovation, leading research teams, and advancing drug development programs in various therapeutic areas.

John F. Reilly completed their education with a Ph.D. in Neuroscience from the University of California, Davis, which they pursued from 1992 to 1997. Prior to that, they earned their B.A. in Molecular & Cell Biology from the University of California, Berkeley, where they studied from 1987 to 1991.